Caribou Biosciences, Inc.
CRBU- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001619856
No open-market purchases or sales by Caribou Biosciences, Inc. insiders were filed in the last 90 days; 137 institutions reported holding it in 13F filings for Q2 2026, worth $84.8M in total; Maverick Capital is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Caribou Biosciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Caribou Biosciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Kelly Timothy P | Chief Technology Officer | 73,125 | Feb 27, 2026 | 2 |
| McClung Barbara G | Chief Legal Officer | 481,564 | Feb 24, 2026 | 1 |
| Khan Ruhi Ahmad | Chief Business Officer | 104,998 | Feb 24, 2026 | 1 |
| Albertson Tina M. | Chief Medical Officer | 68,523 | Feb 24, 2026 | 1 |
| Guggenhime Andrew | Director | – | Feb 20, 2026 | 1 |
| Braunstein Scott | Director | – | Feb 20, 2026 | 1 |
| Haurwitz Rachel E. | President and CEO | 447,150 | Feb 20, 2026 | 1 |
| Sacks Natalie | Director | – | Feb 20, 2026 | 1 |
| Johnson David Lee | Director | – | Feb 20, 2026 | 1 |
| Ryali Sriram | Chief Financial Officer | 72,360 | Feb 20, 2026 | 1 |
| Whiting Nancy | Director | – | Feb 20, 2026 | 1 |
| Zheng Ran | Director | – | Feb 20, 2026 | 1 |
| Richardson-Heron Dara | Director | – | Feb 20, 2026 | 1 |
| Kanner Steven | Chief Scientific Officer | 431,556 | Feb 21, 2025 | 0 |
| Fischesser Ryan | VP of Finance and Controller | 118,854 | Nov 22, 2024 | 0 |
| O'Byrne Jason | Chief Financial Officer | 59,224 | Feb 22, 2024 | 0 |
| Rizvi Syed Ali-aamir | Chief Medical Officer | 59,373 | Feb 23, 2023 | 0 |
| FMR LLC | Other: See Remark 1 | 1,464,775Indirect | Jul 29, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2026 (view filing) | Feb 25 | 2 days | Kelly Timothy PChief Technology Officer | SSale | −6.23K | $1.93 | −$12.0K | −7.8%73.1K after | |
| Feb 24, 2026 (view filing) | Feb 24 | Same day | Albertson Tina M.Chief Medical Officer | SSale | −1.07K | $1.96 | −$2.09K | −1.5%68.5K after | 10b5-1 |
| Feb 24, 2026 (view filing) | Feb 24 | Same day | Khan Ruhi AhmadChief Business Officer | SSale | −6.94K | $1.96 | −$13.6K | −6.2%105.0K after | |
| Feb 24, 2026 (view filing) | Feb 24 | Same day | Kelly Timothy PChief Technology Officer | SSale | −3.15K | $1.96 | −$6.17K | −3.8%79.4K after | |
| Feb 24, 2026 (view filing) | Feb 24 | Same day | McClung Barbara GChief Legal Officer | SSale | −6.94K | $1.96 | −$13.6K | −1.4%481.6K after | |
| Mar 17, 2025 (view filing) | Mar 14 | 3 days | Haurwitz Rachel E.President and CEO | PPurchase | +20.0K | $1.02 | +$20.4K | +0.6%3.37M after | |
| Feb 21, 2025 (view filing) | Feb 21 | Same day | Khan Ruhi AhmadChief Business Officer | SSale | −3.56K | $1.35 | −$4.81K | −5.1%66.9K after | |
| Feb 21, 2025 (view filing) | Feb 21 | Same day | Kanner StevenChief Scientific Officer | SSale | −3.56K | $1.35 | −$4.81K | −0.8%431.6K after | |
| Feb 21, 2025 (view filing) | Feb 21 | Same day | McClung Barbara GChief Legal Officer | SSale | −3.56K | $1.35 | −$4.81K | −0.8%443.5K after | |
| Jan 30, 2025 (view filing) | Jan 29 | 1 day | Ryali SriramChief Financial Officer | PPurchase | +17.4K | $1.42 | +$24.7K | New position17.4K after | |
| Jan 20, 2023 (view filing) | Jan 19 | 1 day | Rizvi Syed Ali-aamirChief Medical Officer | SSale | −5.63K | $6.31 | −$35.5K | −8.7%59.4K after | |
| Oct 7, 2022 (view filing) | Oct 6 | 1 day | Fischesser RyanVP of Finance and Controller | SSale | −10.0K | $10.80 | −$108.0K | −8.3%110.4K after | |
| Aug 26, 2022 (view filing) | Aug 25 | 1 day | Kanner StevenChief Scientific Officer | SSale | −43.2K | $11.22 | −$485.2K | −12.5%302.1K after | |
| Jan 12, 2022 (view filing) | Jan 11 | 1 day | Fischesser RyanVP of Finance and Controller | PPurchase | +7.39K | $4.00 | +$29.6K | +7.3%109.1K after | 2 lots |
| Dec 21, 2021 (view filing) | Dec 20 | 1 day | Fischesser RyanVP of Finance and Controller | PPurchase | +1.14K | $2.69 | +$3.06K | +1.1%101.7K after | |
| Dec 8, 2021 (view filing) | Dec 7 | 1 day | McClung Barbara GChief Legal Officer | PPurchase | +6.13K | $2.69 | +$16.5K | +1.8%349.0K after | 2 lots |
| Oct 21, 2021 (view filing) | Oct 20 | 1 day | McClung Barbara GChief Legal Officer | PPurchase | +9.22K | $2.69 | +$24.8K | +2.8%342.8K after | 2 lots |
| Oct 13, 2021 (view filing) | Oct 12 | 1 day | Kanner StevenChief Scientific Officer | PPurchase | +114.9K | $1.92 | +$220.8K | +114.7%215.0K after | 3 lots |
| Oct 12, 2021 (view filing) | Oct 11 | 1 day | Fischesser RyanVP of Finance and Controller | PPurchase | +1.75K | $2.69 | +$4.70K | +1.8%100.6K after |